105 studies found for:    INCB018424 | Exclude Unknown
Show Display Options
Rank Status Study
1 Completed A Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: INCB018424 phosphate cream;   Drug: Dovonex® calcipotriene 0.005%;   Drug: Diprolene® AF betamethasone dipropionate 0.05% cream.;   Drug: Placebo cream
2 Active, not recruiting INCB018424 in Patients With Advanced Hematologic Malignancies
Conditions: Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia
Intervention: Drug: INCB018424
3 Completed
Has Results
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Condition: Myelofibrosis
Intervention: Drug: Ruxolitinib
4 Recruiting Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Condition: Leukemia
Interventions: Drug: Ruxolitinib;   Drug: TKI
5 Active, not recruiting
Has Results
Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Ruxolitinib
6 Recruiting Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Conditions: Primary Myelofibrosis;   Post Essential Thrombocythemia-myelofibrosis;   Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
7 Not yet recruiting Study of Ruxolitinib for Patients With Myelofibrosis (MF)
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Behavioral: Questionnaires
8 Terminated
Has Results
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Condition: Metastatic Prostate Cancer
Intervention: Drug: Ruxolitinib
9 Recruiting Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML)
Conditions: Leukemia;   Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib;   Drug: Decitabine
10 Completed A Dose Ranging Study of the Effect of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: INCB018424 Phosphate Cream;   Drug: Placebo Cream
11 Recruiting Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
Condition: Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib;   Drug: Pracinostat;   Behavioral: Questionnaire
12 Recruiting Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
Condition: Leukemia
Interventions: Drug: Ruxolitinib;   Drug: Dasatinib;   Drug: Rituximab;   Drug: G-CSF;   Drug: Pegfilgrastim;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Solumedrol;   Drug: 6-mercaptopurine;   Drug: Prednisone;   Drug: Leucovorin
13 Active, not recruiting
Has Results
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis;   Polycythemia Vera;   Thrombocytosis
Intervention: Drug: Ruxolitinib
14 Recruiting A Study With INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
Condition: Alopecia Areata
Interventions: Drug: Placebo Cream;   Drug: INCB018424 Phosphate Cream
15 Recruiting Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Condition: Leukemia
Intervention: Drug: Ruxolitinib
16 Completed
Has Results
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Ruxolitinib 25 mg;   Drug: Dexamethasone 40 mg
17 Completed
Has Results
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Drug: Placebo
18 Completed
Has Results
A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: INCB018424;   Drug: Placebo
19 Recruiting Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL): Phase II
Condition: Leukemia
Interventions: Drug: Ruxolitinib;   Behavioral: Questionnaire
20 Active, not recruiting Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
Condition: Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib;   Drug: Lenalidomide;   Drug: Prednisone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years